CLB

Core Laboratories Inc

Add to Watchlist

Advanced Chart

12.050

-0.290(-2.350%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

12.450

Open

12.060

VWAP

12.14

Vol

362.38K

Mkt Cap

564.94M

Low

12.030

Amount

4.40M

EV/EBITDA(TTM)

9.73

Total Shares

46.66M

686.76M

EV/OCF(TTM)

11.94

P/S(TTM)

1.13

Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. In addition, the Company assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. The Company has two segments. Reservoir Description segment provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry. In addition, it provides reservoir description capabilities. Production Enhancement segment provides integrated diagnostic services. The Company has approximately 70 offices in more than 50 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

130.03M

-0.42%

0.197

-10.6%

133.93M

-0.34%

0.227

-9.33%

134.71M

+4.23%

0.213

-3.03%

Estimates Revision

The market is revising Downward the revenue expectations for Core Laboratories Inc. (CLB) for FY2025, with the revenue forecasts being adjusted by -3.79% over the past three months. During the same period, the stock price has changed by -27.84%.

Revenue Estimates for FY2025

Revise Downward

-3.79%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.9%

In Past 3 Month

Stock Price

Go Down

-27.84%

In Past 3 Month

3 Analyst Rating

16.18% Upside

Wall Street analysts forecast CLB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLB is 14.00 USD with a low forecast of 13.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

1 Sell

Moderate Sell

16.18% Upside

Current: 12.050

Low

13.00

Averages

14.00

High

16.00

16.18% Upside

Current: 12.050

Low

13.00

Averages

14.00

High

16.00

Stifel

Stephen Gengaro

Hold

Maintains

$19 → $15

2025-04-15

Reason

Stifel

Stephen Gengaro

Price Target

$19 → $15

2025-04-15

Maintains

Hold

Reason

Citigroup

Scott Gruber

Strong Sell

Hold

Upgrades

$15 → $16

2025-03-12

Reason

Citigroup

Scott Gruber

Price Target

$15 → $16

2025-03-12

Upgrades

Strong Sell

Hold

Reason

Citigroup

Scott Gruber

Strong Sell

Maintains

$14 → $15

2025-02-20

Reason

Citigroup

Scott Gruber

Price Target

$14 → $15

2025-02-20

Maintains

Strong Sell

Reason

Citi raised the firm's price target on Core Laboratories to $15 from $14 and keeps a Sell rating on the shares. The firm updated the company's model post the earnings report.

Citigroup

Scott Gruber

Strong Sell

Maintains

$15 → $14

2024-10-31

Reason

Citigroup

Scott Gruber

Price Target

$15 → $14

2024-10-31

Maintains

Strong Sell

Reason

Stifel

Stephen Gengaro

Hold

Maintains

$18 → $22

2024-07-26

Reason

Stifel

Stephen Gengaro

Price Target

$18 → $22

2024-07-26

Maintains

Hold

Reason

Piper Sandler

Luke Lemoine

Hold

Maintains

$18 → $17

2024-07-15

Reason

Piper Sandler

Luke Lemoine

Price Target

$18 → $17

2024-07-15

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Core Laboratories Inc (CLB.N) is 15.63, compared to its 5-year average forward P/E of 28.39. For a more detailed relative valuation and DCF analysis to assess Core Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

28.39

Current PE

15.63

Overvalued PE

38.81

Undervalued PE

17.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

16.67

Current EV/EBITDA

10.27

Overvalued EV/EBITDA

21.39

Undervalued EV/EBITDA

11.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.07

Current PS

1.09

Overvalued PS

2.69

Undervalued PS

1.45